Expression of Calsarcin-1 in myocardial hypertrophy process and function of telmisartan treatment

Xin-zheng LU,Xiao-hui YANG,Jia-xin YE,Wen-na ZONG,Jun-hong WANG,Yong-hong YONG,Ke-jiang CAO,Jun HUANG
DOI: https://doi.org/10.3969/j.issn.1001-1978.2012.09.016
2012-01-01
Abstract:Aim: To test Calsarcin-1 level in different stages of cardiac hypertrophy by renovascular hypertensive (2K1C, two-kidneys, oneclip) rat models, and to explore the mechanism of cardiac hypertrophy and the effect of telmisartan. Methods: Forty male Sprague-Dawly rats were randomly divided into sham operation group (n = 10), 2 kidney 1 clip (2K1C) group (n = 15) and telmisartan group (n = 15). 2K1C hypertensive rats were established by chronic partial occlusion of left renal artery. Before and after four and eight weeks of the operation, blood pressure was tested by arterial catheterization, the myocardial structure and function was obtained by ultrasonography, and Calsarcin-1 expression level in myocardium was compared by Western blot. Results: (1) Eight weeks later, the blood pressure and the thickness of left ventricle in 2K1C group were significantly higher than those of sham group (P < 0.01). Compared with 2K1C group, the blood pressure and the the thickness of left ventricle were significantly decreased in telmisartan group (P < 0.01). (2) Compared with sham group, the Calsarcin-1 level was markedly increased in 2K1C group (P < 0.01), and after being treated for 4 weeks, the Calsarcin-1 level was higher than that of untreated group (P < 0.05), but Calsarcin-1 level was not markedly increased after being treated for 4 weeks (P > 0.05). Conclusions: The decreased myocardial calsarcin-1 level participates in cardiac hypertrophy development, Telmisartan increases myocardial Calsarcin-1 level expression, which may be one of its mechanisms in reversing cardiac hypertrophy.
What problem does this paper attempt to address?